Investors Lay $5m On Savonix's Vision To Make Cognitive Data 'Cheap, Fast, Easy' To Access
Savonix has raised $5.1m to further advance its mobile app-based cognitive assessment tool used by clinicians to help develop their patients' treatment plan. The company's founder and CEO, Mylea Charvat, said the 30-minute assessment is faster and much more cost-effective than conventional paper and pen testing, and opens the door for better outcomes for patients who otherwise wouldn't have access to cognitive testing.
You may also be interested in...
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.
On this week’s podcast, Medtech Insight's Reed Miller, Marion Webb and Barnaby Pickering provide a recap of our J.P. Morgan Health Care conference coverage including Abbott, Dexcom, Zimmer Biomet and Nuvasive and spotlight Scottish company PneumoWave.
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.